131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat

Inclusion Criteria:

- Patients must be > 24 months and < 30 years of age when registered on study.

- Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than
a partial response to standard treatment or persistent neuroblastoma that had at least
a partial response to frontline therapy frontline therapy with > 3 residual lesions on
end-induction MIBG scan.

- Patients must have evidence of MIBG uptake into tumor at ≥ one site within 4 weeks
prior to entry on study and subsequent to any intervening therapy.

- Patients must have adequate heart, kidney, liver and bone marrow function. Patients
who have bone marrow disease must still have adequate bone marrow function to enter
the study.

- Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable
CD34+ cells/kg available.

Exclusion Criteria:

- They have had previous I-131 MIBG therapy

- They have other medical problems that could get much worse with this treatment.

- They are pregnant or breast feeding.

- They have a history of a venous or arterial thrombosis that was not associated to a
central line.

- They have active infections such as hepatitis or fungal infections.

- They have active diarhhea.

- They have had an allogeneic stem cell transplant (received stem cell from someone
else)

- They can't cooperate with the special precautions that are needed for this trial.